Dr. Han on the Importance of pCR in Breast Cancer

Video

In Partnership With:

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Heather ​S. Han, MD, medical oncologist and research director of Breast Oncology, Moffitt Cancer Center, discusses the importance of pathologic complete response (pCR) in breast cancer.

Patients with breast cancer who achieve a pCR following neoadjuvant therapy often have a better outcome compared with patients who do not, Han says. Moreover, pCR has been established as an important prognostic marker in breast cancer. 

Today, pCR continues to be used as a surrogate marker for patients with breast cancer ​following neoadjuvant therapy, explains Han.

Based on available data, the field can better determine the most optimal adjuvant treatment option for patients, Han concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD